42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose response (efficacy), safety, and
tolerability of orally administered AKB-6548 in pre-dialysis subjects with anemia with repeat
dosing for 42 days.